Abstract

EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call